Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.

Literature DB >> 31951646

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.

Piers Blombery^1,2,3, Ella R Thompson^1,3, Tamia Nguyen¹, Richard W Birkinshaw^3,4, Jia-Nan Gong^3,4, Xiangting Chen¹, Michelle McBean¹, Rachel Thijssen^3,4, Thomas Conway¹, Mary Ann Anderson^2,3,4, John F Seymour^2,3, David A Westerman^1,2,3, Peter E Czabotar^3,4, David C S Huang^3,4, Andrew W Roberts^2,3,4.

Abstract

Entities: Disease Gene Mutation

Mesh：

Substances：

Year: 2020 PMID： 31951646 PMCID： PMC7146015 DOI： 10.1182/blood.2019004205

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

× No keyword cloud information.

19 in total

1. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.

Authors: Piers Blombery; Mary Ann Anderson; Jia-Nan Gong; Rachel Thijssen; Richard W Birkinshaw; Ella R Thompson; Charis E Teh; Tamia Nguyen; Zhen Xu; Christoffer Flensburg; Thomas E Lew; Ian J Majewski; Daniel H D Gray; David A Westerman; Constantine S Tam; John F Seymour; Peter E Czabotar; David C S Huang; Andrew W Roberts
Journal: Cancer Discov Date: 2018-12-04 Impact factor: 39.397

2. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Authors: John F Seymour; Shuo Ma; Danielle M Brander; Michael Y Choi; Jacqueline Barrientos; Matthew S Davids; Mary Ann Anderson; Anne W Beaven; Steven T Rosen; Constantine S Tam; Betty Prine; Suresh K Agarwal; Wijith Munasinghe; Ming Zhu; L Leanne Lash; Monali Desai; Elisa Cerri; Maria Verdugo; Su Young Kim; Rod A Humerickhouse; Gary B Gordon; Thomas J Kipps; Andrew W Roberts
Journal: Lancet Oncol Date: 2017-01-13 Impact factor: 41.316

3. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

Authors: Christin Tse; Alexander R Shoemaker; Jessica Adickes; Mark G Anderson; Jun Chen; Sha Jin; Eric F Johnson; Kennan C Marsh; Michael J Mitten; Paul Nimmer; Lisa Roberts; Stephen K Tahir; Yu Xiao; Xiufen Yang; Haichao Zhang; Stephen Fesik; Saul H Rosenberg; Steven W Elmore
Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701

4. Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?

Authors: Andrew H Wei; Andrew W Roberts
Journal: Cancer Discov Date: 2019-08 Impact factor: 39.397

5. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Authors: Andrew W Roberts; Shuo Ma; Thomas J Kipps; Steven E Coutre; Matthew S Davids; Barbara Eichhorst; Michael Hallek; John C Byrd; Kathryn Humphrey; Lang Zhou; Brenda Chyla; Jacqueline Nielsen; Jalaja Potluri; Su Young Kim; Maria Verdugo; Stephan Stilgenbauer; William G Wierda; John F Seymour
Journal: Blood Date: 2019-04-25 Impact factor: 22.113

6. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.).

Authors: Jonathan Weiss; Martin Peifer; Carmen D Herling; Lukas P Frenzel; Michael Hallek
Journal: Haematologica Date: 2019-11 Impact factor: 9.941

7. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

Authors: Kirsten Fischer; Othman Al-Sawaf; Jasmin Bahlo; Anna-Maria Fink; Maneesh Tandon; Mark Dixon; Sandra Robrecht; Simon Warburton; Kathryn Humphrey; Olga Samoylova; Anna M Liberati; Javier Pinilla-Ibarz; Stephen Opat; Liliya Sivcheva; Katell Le Dû; Laura M Fogliatto; Carsten U Niemann; Robert Weinkove; Sue Robinson; Thomas J Kipps; Sebastian Boettcher; Eugen Tausch; Rod Humerickhouse; Barbara Eichhorst; Clemens-Martin Wendtner; Anton W Langerak; Karl-Anton Kreuzer; Matthias Ritgen; Valentin Goede; Stephan Stilgenbauer; Mehrdad Mobasher; Michael Hallek
Journal: N Engl J Med Date: 2019-06-04 Impact factor: 91.245

8. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors: Ahmet Zehir; Ryma Benayed; Ronak H Shah; Aijazuddin Syed; Sumit Middha; Hyunjae R Kim; Preethi Srinivasan; Jianjiong Gao; Debyani Chakravarty; Sean M Devlin; Matthew D Hellmann; David A Barron; Alison M Schram; Meera Hameed; Snjezana Dogan; Dara S Ross; Jaclyn F Hechtman; Deborah F DeLair; JinJuan Yao; Diana L Mandelker; Donavan T Cheng; Raghu Chandramohan; Abhinita S Mohanty; Ryan N Ptashkin; Gowtham Jayakumaran; Meera Prasad; Mustafa H Syed; Anoop Balakrishnan Rema; Zhen Y Liu; Khedoudja Nafa; Laetitia Borsu; Justyna Sadowska; Jacklyn Casanova; Ruben Bacares; Iwona J Kiecka; Anna Razumova; Julie B Son; Lisa Stewart; Tessara Baldi; Kerry A Mullaney; Hikmat Al-Ahmadie; Efsevia Vakiani; Adam A Abeshouse; Alexander V Penson; Philip Jonsson; Niedzica Camacho; Matthew T Chang; Helen H Won; Benjamin E Gross; Ritika Kundra; Zachary J Heins; Hsiao-Wei Chen; Sarah Phillips; Hongxin Zhang; Jiaojiao Wang; Angelica Ochoa; Jonathan Wills; Michael Eubank; Stacy B Thomas; Stuart M Gardos; Dalicia N Reales; Jesse Galle; Robert Durany; Roy Cambria; Wassim Abida; Andrea Cercek; Darren R Feldman; Mrinal M Gounder; A Ari Hakimi; James J Harding; Gopa Iyer; Yelena Y Janjigian; Emmet J Jordan; Ciara M Kelly; Maeve A Lowery; Luc G T Morris; Antonio M Omuro; Nitya Raj; Pedram Razavi; Alexander N Shoushtari; Neerav Shukla; Tara E Soumerai; Anna M Varghese; Rona Yaeger; Jonathan Coleman; Bernard Bochner; Gregory J Riely; Leonard B Saltz; Howard I Scher; Paul J Sabbatini; Mark E Robson; David S Klimstra; Barry S Taylor; Jose Baselga; Nikolaus Schultz; David M Hyman; Maria E Arcila; David B Solit; Marc Ladanyi; Michael F Berger
Journal: Nat Med Date: 2017-05-08 Impact factor: 53.440

9. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.

Authors: Carmen D Herling; Nima Abedpour; Jonathan Weiss; Anna Schmitt; Ron Daniel Jachimowicz; Olaf Merkel; Maria Cartolano; Sebastian Oberbeck; Petra Mayer; Valeska Berg; Daniel Thomalla; Nadine Kutsch; Marius Stiefelhagen; Paula Cramer; Clemens-Martin Wendtner; Thorsten Persigehl; Andreas Saleh; Janine Altmüller; Peter Nürnberg; Christian Pallasch; Viktor Achter; Ulrich Lang; Barbara Eichhorst; Roberta Castiglione; Stephan C Schäfer; Reinhard Büttner; Karl-Anton Kreuzer; Hans Christian Reinhardt; Michael Hallek; Lukas P Frenzel; Martin Peifer
Journal: Nat Commun Date: 2018-02-20 Impact factor: 14.919

10. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.

Authors: Richard W Birkinshaw; Jia-Nan Gong; Cindy S Luo; Daisy Lio; Christine A White; Mary Ann Anderson; Piers Blombery; Guillaume Lessene; Ian J Majewski; Rachel Thijssen; Andrew W Roberts; David C S Huang; Peter M Colman; Peter E Czabotar
Journal: Nat Commun Date: 2019-06-03 Impact factor: 14.919

28 in total

1. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.

Authors: Sigrid S Skånland; Anthony R Mato
Journal: Blood Adv Date: 2021-01-12

2. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.

Authors: Fabienne Lucas; Karylin Larkin; C Thomas Gregory; Shelley Orwick; Tzyy-Jye Doong; Arletta Lozanski; Gerard Lozanski; Shrilekha Misra; Apollinaire Ngankeu; Hatice Gulcin Ozer; Deepa Sampath; Shanmugapriya Thangavadivel; Selen A Yilmaz; Kerry A Rogers; John C Byrd; Jennifer A Woyach; James S Blachly
Journal: Blood Date: 2020-06-11 Impact factor: 22.113

3. Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells.

Authors: Po Yee Mak; Wenjing Tao; Bing Z Carter; Qi Zhang; Vivian Ruvolo; Vinitha M Kuruvilla; Xiangmeng Wang; Duncan H Mak; Venkata L Battula; Marina Konopleva; Elias J Jabbour; Paul E Hughes; Xiaoyue Chen; Phuong K Morrow; Michael Andreeff
Journal: Mol Cancer Ther Date: 2022-06-01 Impact factor: 6.009

4. Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism.

Authors: Stephen Jun Fei Chong; Kartini Iskandar; Jolin Xiao Hui Lai; Jianhua Qu; Deepika Raman; Rebecca Valentin; Charles Herbaux; Mary Collins; Ivan Cherh Chiet Low; Thomas Loh; Matthew Davids; Shazib Pervaiz
Journal: Nucleic Acids Res Date: 2020-12-16 Impact factor: 16.971

5. BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.

Authors: Tamara Vervloessem; Binu K Sasi; Elena Xerxa; Spyridoula Karamanou; Justin Kale; Rita M La Rovere; Supriya Chakraborty; Flore Sneyers; Meike Vogler; Anastassios Economou; Luca Laurenti; David W Andrews; Dimitar G Efremov; Geert Bultynck
Journal: Cell Death Dis Date: 2020-09-17 Impact factor: 8.469

Review 6. An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy.

Authors: Jared A Cohen; Riccardo Bomben; Federico Pozzo; Erika Tissino; Andrea Härzschel; Tanja Nicole Hartmann; Antonella Zucchetto; Valter Gattei
Journal: Cancers (Basel) Date: 2020-04-07 Impact factor: 6.639

7. DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition.

Authors: Martijn Kerkhofs; Tamara Vervloessem; Kinga B Stopa; Victoria M Smith; Meike Vogler; Geert Bultynck
Journal: Biomolecules Date: 2020-07-21